#DIVISLAB | 🔮 ScoutQuest Crystal Ball
Future business outlook based on management commentary

Outlook: Divi's Laboratories is advancing its generics pipeline towards U.S. and European regulatory approvals, with revenue impacts expected by 2026. The company aims to establish a significant presence in the peptide industry long-term. The Kakinada Project (Unit 3) is anticipated to enhance capacity and support growth. Contrast media volumes are expected to increase by 20-30% year-on-year. Pricing pressure in generics is expected to stabilize within 6 months to a year. The company faces logistical challenges due to global shipping disruptions and potential raw material price volatility influenced by Middle Eastern developments and crude oil fluctuations.

Details:(ScoutQuest)

⚡ AI powered update byCheck-outto receive WhatsApp updates faster than twitter/X.